Low-turnover drug molecules: A current challenge for drug metabolism scientists

Drug Metabolism and Disposition

Volumn 43, Issue 12, 2015, Pages 1917-1928

  Hutzler, J Matthew ^a   Ring, Barbara J ^a   Anderson, Shelby R ^a  

^a IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ATAZANAVIR; ATOMOXETINE; CYTOCHROME P450; DIAZEPAM; DICLOFENAC; DISOPYRAMIDE; DRUG METABOLITE; DRUG METABOLIZING ENZYME; GLIMEPIRIDE; KETOPROFEN; LIDOCAINE; MELOXICAM; METOPROLOL; MIDAZOLAM; NAPROXEN; PHENAZONE; PREDNISOLONE; RANITIDINE; RILUZOLE; RISPERIDONE; THEOPHYLLINE; TIMOLOL; TOLBUTAMIDE; UNINDEXED DRUG; VERAPAMIL; VORICONAZOLE; WARFARIN; ZOLMITRIPTAN; ZOLPIDEM; DRUG;

CELL SUSPENSION; CELL TRANSPORT; COCULTURE; CRYOPRESERVATION; CULTURE TECHNIQUE; DONOR SELECTION; DRUG CLEARANCE; DRUG METABOLISM; FIBROBLAST; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER MICROSOME; MATHEMATICAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCIENTIST; TURNOVER TIME; ANIMAL; CELL CULTURE; CHEMISTRY; DRUG EFFECTS; DRUG INACTIVATION; METABOLIC CLEARANCE RATE; METABOLISM; PHYSIOLOGY;

ANIMALS; CELLS, CULTURED; COCULTURE TECHNIQUES; HEPATOCYTES; HUMANS; INACTIVATION, METABOLIC; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; PHARMACEUTICAL PREPARATIONS;

EID: 84949008477     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.066431     Document Type: Review

References (64)

1. Aitio ML (1981) Plasma concentrations and protein binding of disopyramide and mono-Ndealkyldisopyramide during chronic oral disopyramide therapy. Br J Clin Pharmacol 11: 369-375.
2. Anderson S, Luffer-Atlas D, and Knadler MP (2009) Predicting circulating human metabolites: how good are we? Chem Res Toxicol 22:243-256.
3. Ballard TE, Orozco CC, and Obach RS (2014) Generation of major human excretory and circulating drug metabolites using a hepatocyte relay method. Drug Metab Dispos 42: 899-902.
4. Bhatia SN, Toner M, Tompkins RG, and Yarmush ML (1994) Selective adhesion of hepatocytes on patterned surfaces. Ann N Y Acad Sci 745:187-209.
5. Blanchard N, Alexandre E, Abadie C, Lavé T, Heyd B, Mantion G, Jaeck D, Richert L, and Coassolo P (2005) Comparison of clearance predictions using primary cultures and suspensions of human hepatocytes. Xenobiotica 35:1-15.
6. Brown HS, Griffin M, and Houston JB (2007) Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab Dispos 35:293-301.
7. Chan TS, Yu H, Moore A, Khetani SR, and Tweedie D (2013) Meeting the challenge of predicting hepatic clearance of compounds slowly metabolized by cytochrome P450 using a novel hepatocyte model, HepatoPac. Drug Metab Dispos 41:2024-2032.
8. Chen LZ, Rose P, Mao Y, Yong CL, St George R, Huang F, Latli B, Mandarino D, and Li Y (2014) Mass balance and metabolite profiling of steady-state faldaprevir, a hepatitis C virus NS3/4 protease inhibitor, in healthy male subjects. Antimicrob Agents Chemother 58:2369-2376.
9. Choi K, Pfund WP, Andersen ME, Thomas RS, Clewell HJ, and LeCluyse EL (2014) Development of 3D dynamic flow model of human liver and its application to prediction of metabolic clearance of 7-ethoxycoumarin. Tissue Eng Part C Methods 20:641-651.
10. Dalvie D, Obach RS, Kang P, Prakash C, Loi CM, Hurst S, Nedderman A, Goulet L, Smith E, and Bu HZ, et al. (2009) Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem Res Toxicol 22:357-368.
11. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
12. Di L, Atkinson K, Orozco CC, Funk C, Zhang H, McDonald TS, Tan B, Lin J, Chang C, and Obach RS (2013) In vitro-in vivo correlation for low-clearance compounds using hepatocyte relay method. Drug Metab Dispos 41:2018-2023.
13. Di L, Kerns EH, Ma XJ, Huang Y, and Carter GT (2008) Applications of high throughput microsomal stability assay in drug discovery. Comb Chem High Throughput Screen 11:469-476.
14. Di L and Obach RS (2015) Addressing the challenges of low clearance in drug research. AAPS J 17:352-357.
15. Di L, Trapa P, Obach RS, Atkinson K, Bi YA, Wolford AC, Tan B, McDonald TS, Lai Y, and Tremaine LM (2012) A novel relay method for determining low-clearance values. Drug Metab Dispos 40:1860-1865.
16. Diamond S, Boer J, Maduskuie TP, Jr, Falahatpisheh N, Li Y, and Yeleswaram S (2010) Speciesspecific metabolism of SGX523 by aldehyde oxidase and the toxicological implications. Drug Metab Dispos 38:1277-1285.
17. Dixon R and Warrander A (1997) The clinical pharmacokinetics of zolmitriptan. Cephalalgia 17 (Suppl 18):15-20.
18. Duan J, Yong CL, Garneau M, Amad M, Bolger G, De Marte J, Montpetit H, Otis F, Jutras M, and Rhéaume M, et al. (2012) Cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV genotype 1 NS3/4A protease inhibitor. Xenobiotica 42: 164-172.
19. Dunn JC, Yarmush ML, Koebe HG, and Tompkins RG (1989) Hepatocyte function and extracellular matrix geometry: long-term culture in a sandwich configuration. FASEB J 3:174-177.
20. European Medicines Agency (EMA) (2009) ICH guideline M3 (R2) on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals. EMA, London.
21. European Medicines Agency (EMA) (2013) Guideline on the investigation of drug interactions. EMA, London.
22. Fagerholm U (2007) Prediction of human pharmacokinetics-evaluation of methods for prediction of hepatic metabolic clearance. J Pharm Pharmacol 59:803-828.
23. Foti RS and Fisher MB (2004) Impact of incubation conditions on bufuralol human clearance predictions: enzyme lability and nonspecific binding. Drug Metab Dispos 32:295-304.
24. Gao H, Jacobs A, White RE, Booth BP, and Obach RS (2013) Meeting report: metabolites in safety testing (MIST) symposium-safety assessment of human metabolites: what's REALLY necessary to ascertain exposure coverage in safety tests? AAPS J 15:970-973.
25. Griffin SJ and Houston JB (2005) Prediction of in vitro intrinsic clearance from hepatocytes: comparison of suspensions and monolayer cultures. Drug Metab Dispos 33:115-120.
26. Hallifax D, Foster JA, and Houston JB (2010) Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view. Pharm Res 27:2150-2161.
27. Hallifax D and Houston JB (2009) Methodological uncertainty in quantitative prediction of human hepatic clearance from in vitro experimental systems. Curr Drug Metab 10:307-321.
28. Hinderling PH, Bres J, and Garrett ER (1974) Protein binding and erythrocyte partitioning of disopyramide and its monodealkylated metabolite. J Pharm Sci 63:1684-1690.
29. Hop CE, Cole MJ, Davidson RE, Duignan DB, Federico J, Janiszewski JS, Jenkins K, Krueger S, Lebowitz R, and Liston TE, et al. (2008) High throughput ADME screening: practical considerations, impact on the portfolio and enabler of in silico ADME models. Curr Drug Metab 9:847-853.
30. Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, and Webster R, et al. (2009) Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 49: 513-533.
31. Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479.
32. Hutzler JM, Linder CD, Melton RJ, Vincent J, and Daniels JS (2010) In vitro-in vivo correlation and translation to the clinical outcome for CJ-13,610, a novel inhibitor of 5-lipoxygenase. Drug Metab Dispos 38:1113-1121.
33. Hutzler JM, Obach RS, Dalvie D, and Zientek MA (2013) Strategies for a comprehensive understanding of metabolism by aldehyde oxidase. Expert Opin Drug Metab Toxicol 9:153-168.
34. Hutzler JM, Yang YS, Brown C, Heyward S, and Moeller T (2014) Aldehyde oxidase activity in donor-matched fresh and cryopreserved human hepatocytes and assessment of variability in 75 donors. Drug Metab Dispos 42:1090-1097.
35. Khetani SR and Bhatia SN (2008) Microscale culture of human liver cells for drug development. Nat Biotechnol 26:120-126.
36. Koebe HG, Pahernik S, Eyer P, and Schildberg FW (1994) Collagen gel immobilization: a useful cell culture technique for long-term metabolic studies on human hepatocytes. Xenobiotica 24: 95-107.
37. Kola I and Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711-715.
38. Kuperman AV, Kalgutkar AS, Marfat A, Chambers RJ, and Liston TE (2001) Pharmacokinetics and metabolism of a cysteinyl leukotriene-1 receptor antagonist from the heterocyclic chromanol series in rats: in vitro-in vivo correlation, gender-related differences, isoform identification, and comparison with metabolism in human hepatic tissue. Drug Metab Dispos 29:1403-1409.
39. Lau YY, Sapidou E, Cui X, White RE, and Cheng KC (2002) Development of a novel in vitro model to predict hepatic clearance using fresh, cryopreserved, and sandwich-cultured hepatocytes. Drug Metab Dispos 30:1446-1454.
40. Leclercq L, Cuyckens F, Mannens GS, de Vries R, Timmerman P, and Evans DC (2009) Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development. Chem Res Toxicol 22:280-293.
41. Lundquist P, Lööf J, Sohlenius-Sternbeck AK, Floby E, Johansson J, Bylund J, Hoogstraate J, Afzelius L, and Andersson TB (2014) The impact of solute carrier (SLC) drug uptake transporter loss in human and rat cryopreserved hepatocytes on clearance predictions. Drug Metab Dispos 42:469-480.
42. Martignoni M, Groothuis GM, and de Kanter R (2006) Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875-894.
43. McGinnity DF, Soars MG, Urbanowicz RA, and Riley RJ (2004) Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Dispos 32:1247-1253.
44. Nedderman AN, Dear GJ, North S, Obach RS, and Higton D (2011) From definition to implementation: a cross-industry perspective of past, current and future MIST strategies. Xenobiotica 41:605-622.
45. Novik E, Maguire TJ, Chao P, Cheng KC, and Yarmush ML (2010) A microfluidic hepatic coculture platform for cell-based drug metabolism studies. Biochem Pharmacol 79:1036-1044.
46. Obach RS (2001) The prediction of human clearance from hepatic microsomal metabolism data. Curr Opin Drug Discov Devel 4:36-44.
47. Obach RS (2011) Predicting clearance in humans from in vitro data. Curr Top Med Chem 11: 334-339.
48. Obach RS, Margolis JM, and Logman MJ (2007) In vitro metabolism of CP-122,721 ((2S,3S)-2-phenyl-3-[(5-trifluoromethoxy-2-methoxy)benzylamino]piperidine), a non-peptide antagonist of the substance P receptor. Drug Metab Pharmacokinet 22:336-349.
49. Obach RS and Reed-Hagen AE (2002) Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos 30:831-837.
50. Oda S, Fukami T, Yokoi T, and Nakajima M (2015) A comprehensive review of UDPglucuronosyltransferase and esterases for drug development. Drug Metab Pharmacokinet 30:30-51.
51. Ramsden D, Tweedie DJ, Chan TS, Taub ME, and Li Y (2014) Bridging in vitro and in vivo metabolism and transport of faldaprevir in human using a novel cocultured human hepatocyte system, HepatoPac. Drug Metab Dispos 42:394-406.
52. Richert L, Liguori MJ, Abadie C, Heyd B, Mantion G, Halkic N, and Waring JF (2006) Gene expression in human hepatocytes in suspension after isolation is similar to the liver of origin, is not affected by hepatocyte cold storage and cryopreservation, but is strongly changed after hepatocyte plating. Drug Metab Dispos 34:870-879.
53. Ring BJ, Chien JY, Adkison KK, Jones HM, Rowland M, Jones RD, Yates JW, Ku MS, Gibson CR, and He H, et al. (2011) PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessment of prediction methods of human clearance. J Pharm Sci 100:4090-4110.
54. Rowland M, Benet LZ, and Graham GG (1973) Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm 1:123-136.
55. Sarkar U, Rivera-Burgos D, Large EM, Hughes DJ, Ravindra KC, Dyer RL, Ebrahimkhani MR, Wishnok JS, Griffith LG, and Tannenbaum SR (2015) Metabolite profiling and pharmacokinetic evaluation of hydrocortisone in a perfused three-dimensional human liver bioreactor. Drug Metab Dispos 43:1091-1099.
56. Skett P (1994) Problems in using isolated and cultured hepatocytes for xenobiotic metabolism/etabolism-based toxicity testing-Solutions? Toxicol In Vitro 8:491-504.
57. Smith CM, Nolan CK, Edwards MA, Hatfield JB, Stewart TW, Ferguson SS, Lecluyse EL, and Sahi J (2012) A comprehensive evaluation of metabolic activity and intrinsic clearance in suspensions and monolayer cultures of cryopreserved primary human hepatocytes. J Pharm Sci 101:3989-4002.
58. U.S. Food and Drug Administration (USFDA) (2008) Guidance for industry: Safety testing of drug metabolites. USFDA, Silver Spring, MD.
59. U.S. Food and Drug Administration (USFDA) (2012) Guidance for industry: Drug interaction studies-Study design, data analysis, implications for dosing, and label recommendations. USFDA, Silver Spring, MD.
60. Vivares A, Salle-Lefort S, Arabeyre-Fabre C, Ngo R, Penarier G, Bremond M, Moliner P, Gallas JF, Fabre G, and Klieber S (2015) Morphological behaviour and metabolic capacity of cryopreserved human primary hepatocytes cultivated in a perfused multiwell device. Xenobiotica 45:29-44.
61. Walker GS, Bauman JN, Ryder TF, Smith EB, Spracklin DK, and Obach RS (2014) Biosynthesis of drug metabolites and quantitation using NMR spectroscopy for use in pharmacologic and drug metabolism studies. Drug Metab Dispos 42:1627-1639.
62. Wang WW, Khetani SR, Krzyzewski S, Duignan DB, and Obach RS (2010) Assessment of a micropatterned hepatocyte coculture system to generate major human excretory and circulating drug metabolites. Drug Metab Dispos 38:1900-1905.
63. Zhang X, Liu HH, Weller P, Zheng M, Tao W, Wang J, Liao G, Monshouwer M, and Peltz G (2011) In silico and in vitro pharmacogenetics: aldehyde oxidase rapidly metabolizes a p38 kinase inhibitor. Pharmacogenomics J 11:15-24.
64. Zientek MA and Youdim K (2015) Reaction phenotyping: advances in the experimental strategies used to characterize the contribution of drug-metabolizing enzymes. Drug Metab Dispos 43: 163-181.